NCT00603668 · Interventional trial
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
Overall registry status Completed
Phase 1 · Phase 2
Conditions Chronic Lymphocytic Lymphoma
Delaware Valley sites
- University of Pennsylvania Cancer Center · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory